Chinese researchers to test double doses of CanSino's coronavirus vaccine candidate

Credit: REUTERS/THOMAS PETER

Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China's CanSino Biologics Inc and a military-backed research unit, clinical trial registry data showed.

BEIJING, Sept 18 (Reuters) - Researchers plan to start a clinical trial for an additional dose of a coronavirus vaccine candidate co-developed by China's CanSino Biologics Inc 6185.HK and a military-backed research unit, clinical trial registry data showed.

A single dose of the vaccine candidate Ad5-nCoV, one among a handful that China is pursuing, has final-stage trials lined up in Pakistan and Russia. The candidate has been approved for use in the Chinese military.

Scientists outside the company have expressed concern that the effectiveness of Ad5-nCoV, which uses a common cold virus many people have contracted to carry genetic traces of the coronavirus, could be limited.

In response, CanSino said earlier this month there was no evidence that existing immunity against the common cold virus could severely hurt Ad5-nCoV's ability to trigger antibodies against the new coronavirus, citing data gathered from a single dose-based Phase 2 trial.

In July, researchers working on Ad5-nCoV said a flexible additional dose might be able to provide enhanced immune response, based on their previous experience using this method to develop a common cold virus-based Ebola vaccine.

The new two-dose Phase 1 trial will test the safety of two doses and their ability to generate an immune response, showed a registration record published on Thursday. https://bit.ly/35Zzi4r

Researchers expect to recruit 168 healthy adults to take two doses of Ad5-nCoV for the trial estimated to begin on Sept. 20 in China's Wuhan.

A CanSino representative declined to comment on the new trial.

(Reporting by Roxanne Liu and Tony Munroe; Editing by Christopher Cushing)

((hongkong.newsroom@thomsonreuters.com; (8610)6627-1277; Reuters Messaging: roxanne.liu@thomsonreuters.com))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More